Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Ziftomenib in Acute myeloid leukaemia with 11q23 abnormality: NCT07355335 Clinical Landscape Report 2026
28 September 2026
NCT07355335 clinical landscape for Acute myeloid leukaemia with 11q23 abnormality: endpoints, sponsor, phase, geography, readouts, asset context and developm…
9 min read
Hexagen in Eczema: NCT07355075 Clinical Landscape Report 2026
28 September 2026
NCT07355075 clinical landscape for Eczema: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Revumenib in Acute Myeloid Leukemia: NCT07356154 Clinical Landscape Report 2026
28 September 2026
NCT07356154 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PRA-523 in Pruritus: ISRCTN63487177 Clinical Landscape Report 2026
28 September 2026
ISRCTN63487177 clinical landscape for Pruritus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Acute Myeloid Leukemia: NCT07359859 Clinical Landscape Report 2026
28 September 2026
NCT07359859 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
KD01 in Bladder Cancer: NCT07359235 Clinical Landscape Report 2026
28 September 2026
NCT07359235 clinical landscape for Bladder Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CLL1-CD33-NKG2D Bicephali CAR-T(Yake) in Acute Myeloid Leukemia: NCT07370064 Clinical Landscape Report 2026
28 September 2026
NCT07370064 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT07358195 Clinical Landscape Report 2026
28 September 2026
NCT07358195 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LW-402 in Severe Atopic Dermatitis: NCT07370909 Clinical Landscape Report 2026
28 September 2026
NCT07370909 clinical landscape for Severe Atopic Dermatitis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GPRC5D CAR-T Cell(Tianjin First Central Hospital) in Recurrent Multiple Myeloma: NCT07365059 Clinical Landscape Report 2026
28 September 2026
NCT07365059 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tacrolimus in Eczema: NCT07367932 Clinical Landscape Report 2026
28 September 2026
NCT07367932 clinical landscape for Eczema: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dupilumab Biosimilar (Chong Kun Dang Pharmaceutical) in Dermatitis, Atopic: NCT07358156 Clinical Landscape Report 2026
28 September 2026
NCT07358156 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.